AndroGel vs Jatenzo in Special Populations: A Head-to-Head Clinical Comparison

How Each Drug Delivers Testosterone

AndroGel and Jatenzo take completely different routes to raise serum testosterone, and those routes explain most of the special-population differences that follow.

AndroGel: Transdermal Absorption

AndroGel 1.62% delivers testosterone through the skin. Applied once daily to shoulders or upper arms, the gel forms a reservoir in the stratum corneum and releases testosterone steadily over 24 hours. Because absorption bypasses the liver entirely, there is no hepatic first-pass metabolism and no risk of the hepatotoxicity historically associated with 17-alpha-alkylated oral androgens. Steady-state is typically reached within 24 to 72 hours of dose adjustment. Absorption efficiency varies by approximately 9 to 14% depending on application site, skin hydration, and ambient temperature.

The FDA-approved dose range is 20.25 mg to 81 mg of testosterone per day. In the T-Trials (N=788 men aged 65 and older with confirmed hypogonadism), AndroGel raised mean serum testosterone from roughly 234 ng/dL at baseline to 500 to 550 ng/dL, a normalization rate confirmed across the seven sub-trials.

Jatenzo: Lymphatic Oral Absorption

Jatenzo uses testosterone undecanoate, a long-chain fatty-acid ester, formulated in a lipid excipient. After ingestion with food, it is absorbed through intestinal lymphatics rather than the portal vein, which is why it avoids significant hepatic first-pass degradation despite being an oral product. The FDA prescribing information confirms this lymphatic pathway.

Swerdloff et al. (J Clin Endocrinol Metab 2020, N=166) demonstrated that twice-daily Jatenzo normalized serum testosterone (300 to 1,000 ng/dL) in 87% of hypogonadal men at their final titrated dose. Mean Cavg was 498 ng/dL. The dose range is 158 mg to 396 mg twice daily, and every dose must be taken with a meal containing at least some fat.

Cardiovascular Risk: The Most Consequential Difference

Jatenzo carries a Black Box Warning for increases in blood pressure that may raise the risk of major adverse cardiovascular events (MACE). AndroGel does not carry this box warning. This single regulatory difference reshapes prescribing decisions for roughly 30 to 40% of men presenting for TRT, because hypertension is the most common comorbidity in that population.

Blood Pressure Data for Jatenzo

In Swerdloff et al. 2020, mean systolic blood pressure increased by 3.7 mmHg and diastolic by 1.8 mmHg from baseline in the Jatenzo arm. While modest at a population level, a 3 to 4 mmHg systolic rise is clinically meaningful in a patient already at 145/90 mmHg. The FDA-mandated label states: "Increases in blood pressure can occur with JATENZO and may increase the risk of MACE." Providers are instructed to monitor blood pressure before starting therapy and at every follow-up visit.

Blood Pressure Data for AndroGel

The TRAVERSE trial (N=5,246, mean age 57, published in NEJM 2023) was the largest cardiovascular outcomes trial in testosterone therapy to date. Testosterone replacement using gel formulations did not increase MACE compared with placebo (hazard ratio 0.96, 95% CI 0.83 to 1.12) in men with hypogonadism and high cardiovascular risk. Systolic blood pressure changes were small and not significantly different from placebo over a median 33 months of follow-up.

Practical Guidance for High-BP Patients

For men with stage 2 hypertension (systolic >160 mmHg) or recent MACE, AndroGel is generally the preferred starting agent. Jatenzo may still be used if gel application is not feasible, but blood pressure requires monitoring at 4 weeks, 12 weeks, and every 6 months thereafter per the Jatenzo prescribing label.

Obesity and Metabolic Syndrome

Men with BMI >30 represent a large share of the hypogonadal population. Low testosterone and obesity form a self-reinforcing cycle: adipose tissue aromatizes testosterone to estradiol, suppressing LH and further lowering T production.

How Obesity Affects Jatenzo Absorption

Jatenzo's lymphatic absorption is fat-dependent. Higher dietary fat content at the time of dosing increases Cmax and AUC, which benefits obese patients who may eat larger, higher-fat meals. In the Swerdloff pharmacokinetic sub-study, men who consumed a high-fat meal showed approximately 40% greater AUC compared with a low-fat meal. Obese patients therefore tend to achieve target serum testosterone with lower or mid-range doses of Jatenzo. Paradoxically, if a patient skips the fat-containing meal, absorption can fall sharply.

How Obesity Affects AndroGel Absorption

Transdermal testosterone absorption is largely independent of dietary fat. However, increased subcutaneous adipose tissue at application sites may modestly reduce flux into the systemic circulation. Obese men on AndroGel sometimes require doses at the higher end of the range (81 mg/day) to achieve Cavg >300 ng/dL. The Endocrine Society's 2018 clinical practice guideline notes that dose titration should target mid-normal range testosterone.

Metabolic Syndrome Considerations

The 2018 Endocrine Society guideline recommends against starting testosterone therapy in men with untreated severe obstructive sleep apnea, a condition common in obese patients. Neither AndroGel nor Jatenzo is contraindicated in metabolic syndrome per se, but the cardiovascular monitoring requirements for Jatenzo make it more burdensome in this population, which already carries elevated baseline cardiovascular risk.

Skin-Transfer Risk and Household Safety

Skin transfer is a documented safety problem specific to AndroGel. Jatenzo, as an oral capsule, carries no dermal transfer risk at all.

Documented Cases of Secondary Exposure

The FDA has received post-marketing reports of virilization in female partners and prepubertal children following AndroGel skin contact. The AndroGel label carries a Black Box Warning advising patients to wash hands thoroughly after application, cover the application site with clothing, and shower before physical contact. Despite these precautions, secondary exposure events continue to be reported.

A 2009 FDA safety communication specifically cited cases of children developing premature pubic hair, clitoromegaly, and advanced bone age after contact with male caregivers using testosterone gels. The Endocrine Society guideline explicitly flags this risk for men living with young children or female partners trying to conceive.

When Jatenzo Has a Clear Advantage

Any hypogonadal man living with a child under 12, a pregnant partner, or a partner with estrogen-sensitive conditions should strongly consider Jatenzo over AndroGel specifically to eliminate transfer risk. The twice-daily dosing is a trade-off, but the safety profile in these households is unambiguous.

Hepatic Impairment

Both drugs bypass classic hepatic first-pass metabolism, but their hepatic profiles are not identical.

AndroGel and Liver Function

Transdermal testosterone does not require hepatic processing for absorption and does not produce the hepatotoxic 17-alpha-alkylated metabolites associated with oral methyltestosterone. Long-term observational data show no clinically significant liver enzyme elevations with gel formulations at therapeutic doses. In patients with compensated cirrhosis (Child-Pugh A), AndroGel is generally considered safe with standard LFT monitoring.

Jatenzo and Liver Function

Jatenzo's prescribing information notes that formal pharmacokinetic studies in patients with hepatic impairment have not been conducted and recommends caution. Testosterone undecanoate undergoes some hepatic esterase-mediated cleavage after lymphatic delivery, meaning impaired hepatic function could theoretically alter free testosterone availability. In men with Child-Pugh B or C liver disease, AndroGel is the more data-supported option by default.

Hematocrit and Polycythemia Risk

Both agents raise hematocrit above 54% in a subset of patients, but the rate and timing differ.

Testosterone stimulates erythropoiesis via EPO and direct bone marrow effects. In the T-Trials, AndroGel raised hematocrit by a mean of 3.8 percentage points over 12 months, with polycythemia (hematocrit >54%) occurring in approximately 7.5% of the treated group versus 1.7% placebo. In Swerdloff et al. 2020, Jatenzo raised hematocrit by a mean of 4.0 percentage points; 21% of subjects experienced hematocrit >54% at some point during the trial.

The higher polycythemia rate with Jatenzo may reflect its pharmacokinetic profile: twice-daily dosing produces two Cmax peaks per day, which could provide greater cumulative erythropoietic stimulus. The Endocrine Society recommends checking hematocrit at 3 to 6 months after starting therapy and annually thereafter, with dose reduction or therapeutic phlebotomy if hematocrit exceeds 54%. Men with baseline hematocrit >50% or a history of polycythemia vera should not receive either agent until that is addressed.

Pharmacokinetic Variability and Monitoring Burden

AndroGel Serum Level Predictability

AndroGel produces a relatively flat pharmacokinetic curve. Serum testosterone rises within 2 hours of application and remains stable across the day, making a single morning trough or mid-morning draw a reliable measure of adequacy. Intra-individual CV for Cavg is approximately 20 to 25%, which is moderate.

Jatenzo Serum Level Variability

Jatenzo generates two distinct peaks per day (roughly 4 to 6 hours after each dose), with trough levels that can fall below 300 ng/dL in some patients between doses. The prescribing information recommends measuring serum testosterone 6 hours after the morning dose to capture a representative concentration. Intra-individual variability is higher than with gel formulations, partly because meal composition at each dosing occasion varies. Patients with inconsistent eating patterns may experience wider swings in serum T.

Patient-Level Monitoring Checklist

The HealthRX clinical team uses the following monitoring intervals for both agents:

• Baseline: serum total testosterone (morning), CBC, PSA, LFTs, blood pressure, lipid panel
• Week 4 to 6: serum testosterone at appropriate sampling time (mid-morning for AndroGel; 6 hours post-morning dose for Jatenzo), blood pressure (Jatenzo-specific)
• Month 3: hematocrit, blood pressure, symptom review
• Month 6: full panel including LFTs, PSA, CBC, blood pressure
• Annually: all of the above plus DRE if PSA >1.4 ng/mL in men under 40 or >1.0 ng/mL above baseline

Switching from AndroGel to Jatenzo: Clinical Protocol

Patients frequently ask about switching, usually because of household skin-transfer concerns, application site reactions, or suboptimal testosterone levels despite maximum AndroGel doses.

Timing the Switch

Stop AndroGel on the morning of the switch day. Begin Jatenzo at 158 mg twice daily with meals that same evening. Do not overlap the two formulations. Because AndroGel has a 24-hour depot effect in the stratum corneum, a single-day overlap could cause supraphysiologic testosterone on day 1.

First Dose-Titration Check

Check serum testosterone at the 6-hour post-morning-dose mark between days 35 and 90. If Cavg falls below 300 ng/dL, increase to 237 mg twice daily. If above 1,050 ng/dL, reduce to 158 mg twice daily. Blood pressure must be checked at the same visit.

Special Considerations During the Switch

Men with pre-existing hypertension switching from AndroGel to Jatenzo should have a blood pressure reading at 2 weeks post-switch, not just at 4 to 6 weeks, given the early blood pressure signal seen in Jatenzo trials. Antihypertensive medication doses may require adjustment. The American Heart Association's hypertension guidelines define stage 2 hypertension as systolic >160 mmHg and recommend pharmacologic treatment before adding agents with known pressor effects.

Renal Impairment

Testosterone and its metabolites are primarily excreted via bile and feces after hepatic conjugation, with a smaller renal component. Neither AndroGel nor Jatenzo requires formal dose adjustment for mild-to-moderate chronic kidney disease (CKD stages 1 to 3). However, CKD stage 4 to 5 patients have elevated baseline cardiovascular risk, which amplifies the blood pressure concern with Jatenzo. The National Kidney Foundation notes that testosterone therapy in CKD requires careful individualization. AndroGel is the lower-risk choice in stage 4 to 5 CKD until more data emerge.

Older Adults (Age 65 and Above)

The T-Trials specifically enrolled men 65 years and older, making it the most strong dataset for this population. Gel-based testosterone (matching AndroGel's delivery mechanism) improved sexual desire, physical function, and bone mineral density in this cohort, with a modest increase in cardiovascular events that did not reach statistical significance in the primary analysis.

Jatenzo has not been studied in a dedicated geriatric trial of comparable size. Older men often take multiple antihypertensives and have less blood pressure reserve, making Jatenzo's pressor effect more consequential. Polypharmacy interactions with CYP3A4 substrates are also more common in older adults; both testosterone formulations are substrates for CYP3A4 to varying degrees, though clinical drug-drug interactions are rarely severe.

The Endocrine Society guideline states: "We suggest that clinicians discuss the potential benefits and risks of testosterone therapy with older men before starting therapy and obtain explicit confirmation from patients that they understand both."

Cost, Access, and Insurance Coverage

AndroGel has been available since 2000 and generic testosterone gel 1.62% is widely available at approximately $50, $80/month for most patients using GoodRx-type discount programs. Jatenzo, approved in 2019, remains brand-only with no generic equivalent as of mid-2025. Cash price is approximately $400, $600/month; insurance coverage varies substantially by formulary tier.

For patients without strong clinical indications for Jatenzo (household skin-transfer concern, application site dermatitis), cost alone is a reasonable reason to remain on AndroGel. If a patient has a skin-transfer concern and cost is prohibitive for Jatenzo, intramuscular testosterone cypionate at $20, $40/month is another option, though it carries its own pharmacokinetic profile and injection-related considerations. See FDA formulary resource for branded testosterone products.

Head-to-Head Summary Table

| Feature | AndroGel 1.62% | Jatenzo | |---|---|---| | Route | Transdermal | Oral (lymphatic) | | Dosing frequency | Once daily | Twice daily with meals | | Black Box Warning | Skin transfer (secondary exposure) | Blood pressure increase | | Polycythemia rate | ~7.5% (T-Trials) | ~21% (Swerdloff 2020) | | Hepatic first-pass | Bypassed | Bypassed (lymphatic) | | BP effect | Neutral (TRAVERSE) | +3.7 mmHg systolic | | Best fit: skin-transfer concern | No | Yes | | Best fit: uncontrolled hypertension | Yes | Caution | | Best fit: Child-Pugh B/C liver disease | Yes | Caution | | Best fit: age >65, multiple comorbidities | More data available | Limited geriatric data | | Generic available | Yes | No |